Skip to main content
SpringerLink
Log in

Interferon-γ in the Treatment of Infectious Diseases

  • Chapter
Cytokines and Chemokines in Infectious Diseases Handbook

Part of the book series: Infectious Disease ((ID))

  • 170 Accesses

Abstract

The interferons (IFNs) were identified and named for their interference with viral infections of eukaryotic cells (1,2). They were divided into three categories, based on the predominant cells of origin: leukocytes (now known collectively as IFN-α), fibroblasts (now known as IFN-β), and T-cells (immune or IFN-γ). These interferons also had important differences in acid stability, molecular size, and activity. IFN-α and IFN-β, and the similar IFN-ω, share similar biochemical properties, gene proximity, induction, receptor, and signaling pathways and are collectively referred to as type I interferons. In contrast, IFN-γ is quite distinct in many of these features and is referred to as a type II interferon. However, all of the interferons have certain parts of the signaling pathways in common, and they all interfere with viral replication.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nagano, Y. and Kojima, Y.(1954) Pouvoir immunisant du virus vaccinal inactive par des rayons ultraviolets. C R. Soc. Biol. (Paris) 148, 1700–1702.

    CAS  Google Scholar 

  2. Isaacs, A. and Lindemann, J. (1957) Virus interferone. I: the interferons. Proc. R. Soc. Biol. (Lond.) 147, 258–267.

    CAS  Google Scholar 

  3. David M. (1995) Transcription factors in interferon signaling. Pharmacol. Ther. 65(2), 149–161.

    PubMed  CAS  Google Scholar 

  4. Frucht, D.M., Fan, S., Siegel, R.M., Visconti, R., and O’Shea, J.J. (2001) Cytokine signal transduction, in Cytokine Therapeutics in Infectious Diseases (Holland, S.M., ed.), Lippincott Williams & Wilkins, Philadelphia, pp. 295–322.

    Google Scholar 

  5. Nguyen, H., Hiscott, J., and Pitha, P.M. (1997) The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 8,293–312.

    PubMed  CAS  Google Scholar 

  6. Wang, J., Wakeham, J., Harkness, R., and Xing, Z. (1999) Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J. Clin. Invest. 103(7), 1023–1029.

    PubMed  CAS  Google Scholar 

  7. Tomura, M., Maruo, S., Mu, J., Zhou, X.Y., Ahn, H.J., Hamaoka, T., et al. (1998) Differential capacities of CD4+, CD8+, and CD4-CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J. Immunol. 160, 3759–3765.

    PubMed  CAS  Google Scholar 

  8. Mountford, A.P., Coulson, P.S., Cheever, A.W., Sher, A., Wilson, R.A., and Wynn, T.A. (1999) Interleukin-12 can directly induce T-helper 1 responses in interferon-gamma (IFN-gamma) receptor-deficient mice, but requires IFN-gamma signalling to downregulate T-helper 2 responses. Immunology 97(4), 588–594.

    PubMed  CAS  Google Scholar 

  9. Boehm, U., Klamp, T., Groot, M., and Howard, J.C. (1997) Cellular responses to interferon-g. Annu. Rev. Immunol. 15, 749–795,

    PubMed  CAS  Google Scholar 

  10. Pien, G.C., Satoskar, A.R., Takeda, K., Akira, S., and Biron, C.A. (2000) Cutting edge: selective IL-18 requirements for induction of compartmental IFN-gamma responses during viral infection. J. Immunol. 165(9), 4787–4791

    PubMed  CAS  Google Scholar 

  11. Humphreys, B.D. and Dubyak, G.R. (1996) Induction of the P2z/P2X7 nucleotide receptor and associated phospholi-pase D activity by lipopolysaccharide and IFN-gamma in the human THP-1 monocytic cell line. J. Immunol. 157(12), 5627–5637.

    PubMed  CAS  Google Scholar 

  12. Lammas, D.A., Stober, C, Harvey, C.J, Kendrick, N., Panchalingam, S., and Kumararatne, D.S. (1997) ATP-in-duced killing of mycobacteria by human macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity 7(3), 433–444.

    PubMed  CAS  Google Scholar 

  13. Murray, H.W. (1996) Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med. 22(Suppl. 4), S456–S461.

    PubMed  Google Scholar 

  14. Darnell, J.E. Jr. (1998) Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J. Interferon Cytokine Res. 18, 549–554.

    PubMed  CAS  Google Scholar 

  15. Nistico, A. and Young, N.S. (1994) Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia. Ann. Intern. Med. 120(6), 463–69.

    PubMed  CAS  Google Scholar 

  16. Murphy, W.J., Welniak, L.A., Taub, D.D., Wiltrout, R.H., Taylor, P.A., Vallera, D.A., et al. (1998) Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Clin. Invest. 102(9), 1742–1748

    PubMed  CAS  Google Scholar 

  17. Yang, Y.G., Dey, B.R., Sergio, J.J., Pearson, D.A., and Sykes, M. (1998) Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J. Clin. Invest. 102(12), 2126–2135.

    PubMed  CAS  Google Scholar 

  18. Saleem, S., Konieczny, B.T., Lowry, R.P., Baddoura, F.K., and Lakkis, F.G. (1996) Acute rejection of vascularized heart allografts in the absence of IFNgamma. Transplantation 62(12), 1908–1911.

    PubMed  CAS  Google Scholar 

  19. Aguet, M., Dembic, Z., and Merlin, G. (1988) Molecular cloning and expression of the human interferon-gamma receptor. Cell 55(2), 273–280.

    PubMed  CAS  Google Scholar 

  20. Bohni, R., Hemmi, S., and Aguet, M. (1994) Signaling steps involving the cytoplasmic domain of the interferon-gamma receptor alpha-subunit are not species-specific. J. Biol. 269(20), 14,541–14,545.

    CAS  Google Scholar 

  21. Hemmi, S., Bohni, R., Stark, G., Di Marco, F., and Aguet, M. (1994) A novel member of the interferon receptor family complements functionality of the murine interferon gamma receptor in human cells. Cell 76(5), 803–810.

    PubMed  CAS  Google Scholar 

  22. Soh, J., Donnelly, R.J., Kotenko, S., Mariano, T. M., Cook, J. R., Wang, N., et al. (1994) Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 76(5), 793–802.

    PubMed  CAS  Google Scholar 

  23. Bach, E.A., Szabo, S.J., Dighe, A.S., Ashkenazi, A., Aguet, M., Murphy, K. M., et al. (1995) Ligand-induced autoregu-lation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science 270(5239), 1215–1218.

    PubMed  CAS  Google Scholar 

  24. Dighe, A.S., Farrar, M.A., and Schreiber, R.D. (1993) Inhibition of cellular responsiveness to interferon-gamma (IFN gamma) induced by overexpression of inactive forms of the IFN gamma receptor. J. Biol. Chem. 268(14), 10,645–10,653.

    CAS  Google Scholar 

  25. Schindler, C. and Darnell, J.E., Jr. (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64, 621–651.

    PubMed  CAS  Google Scholar 

  26. Dorman, S.E. and Holland, S.M., (2000) Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 11(4), 321–333.

    PubMed  CAS  Google Scholar 

  27. Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A., and Stewart, T.A. (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259(5102), 1739–1742.

    PubMed  CAS  Google Scholar 

  28. Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R., et al. (1993) Immune response in mice that lack the interferon-gamma receptor. Science 259(5102), 1742–1745

    PubMed  CAS  Google Scholar 

  29. Lu, B., Ebensperger, C, Dembic, Z., Wang, Y., Kvatyuk, M., Lu, T., et al. (1998) Targeted disruption of the interferon-gamma receptor 2 gene results in severe immune defects in mice. Proc. Natl. Acad. Sci. USA 95, 8233–8238.

    PubMed  CAS  Google Scholar 

  30. Rodig, S.J., Meraz, M.A., White, J.M., Lampe, P.A., Riley, J.K., Arthur CD., et al. (1998) Disruption of the Jakl gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93(3), 373–383.

    PubMed  CAS  Google Scholar 

  31. Nguyen, K.B., Cousens, L.P., Doughty, L.A., Pien, G.C., Durbin, J.E., and Biron, C.A., (2000) Interferon a/b-mediated inhibition and promotion of interferon g: STAT1 resolves a paradox. Nat. Immunol. 1, 70–76.

    PubMed  CAS  Google Scholar 

  32. Dighe, A.S., Richards, E., Old, L.J., and Schreiber, R.D. (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1(6), 447–456.

    PubMed  CAS  Google Scholar 

  33. Dighe, A.S., Campbell, D., Hsieh, C.S., Clarke, S., Greaves, D.R., Gordon, S., et al.(1995) Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. Immunity 3(5), 657–666.

    PubMed  CAS  Google Scholar 

  34. Muller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M., et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264(5167), 1918–1921.

    PubMed  CAS  Google Scholar 

  35. van den Broek, M.F., Muller, U., Huang, S., Zinkernagel, R.M., and Aguet, M. (1995) Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148, 5–18.

    PubMed  Google Scholar 

  36. Week, K.E., Dal Canto, A.J., Gould, J.D., O’Guin, A.K., Roth, K.A., Saffitz, J.E., et al.(1997) Murine gamma-herpes-virus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat. Med. 3(12), 1346–1353.

    Google Scholar 

  37. Yap, G.S. and Sher, A. (1999) Effector cells of both nonhemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J. Exp. Med. 189(7), 1083–1092.

    CAS  Google Scholar 

  38. Tanaka, Y., Nakashima, H., Hisano, C, Kohsaka, T., Nemoto, Y., Niiro, H., et al. (1999) Association of the interferon-gamma receptor variant (Vall 4 Met) with systemic lupus erythematosus. Immunogenetics 49(4), 266–271.

    PubMed  CAS  Google Scholar 

  39. Nakashima, H., Inoue, H., Akahoshi, M., Tanaka, Y., Yamaoka, K., Ogami, E., et al. (1999) The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEES Lett. 453(1–2), 187–190.

    CAS  Google Scholar 

  40. Dorman, S.E., Uzel, G., Roesler, J., Bradley, J.S., Bastian, J., Billman, G., et al.(1999) Viral infections in interferon-gamma receptor deficiency. J. Pediatr. 135(5), 640–643.

    PubMed  CAS  Google Scholar 

  41. Nathan, C.F., Murray, H.W., Wiebe, M.E., and Rubin, B.Y. (1983) Identification of interferon-gamma as the lymphok-ine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158(3), 670–689.

    PubMed  CAS  Google Scholar 

  42. Nathan, C.F., Horowitz, C.R., de la Harpe, J., Vadhan-Raj, S., Sherwin, S.A., Oettgen, H.F., et al. (1985) Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc. Natl. Acad. Sci. USA 82(24), 8686–8690.

    PubMed  CAS  Google Scholar 

  43. Segal, B.H., Leto, T.L., Gallin, J.I., Malech, H.L., and Holland, S.M. (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Bait.) 79(3), 170–200.

    CAS  Google Scholar 

  44. Gallin, J.I., Sechler, J.M., and Malech, H.L. (1998) Reconstitution of defective phagocyte function in chronic granulomatous disease of childhood with recombinant human interferon-gamma. Trans. Assoc. Am. Physicians 101, 12–17.

    Google Scholar 

  45. Sechler, J.M., Malech, H.L., White, C.J., and Gallin, J.I. (1988) Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc. Natl. Acad. Sci. USA 85(13), 4874–4878.

    PubMed  CAS  Google Scholar 

  46. Ezekowitz, R.A, Orkin, S.H., and Newburger, P.E. (1987) Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J. Clin. Invest. 80(4), 1009–1016.

    PubMed  CAS  Google Scholar 

  47. Newburger, P.E., Ezekowitz, R.A., Whitney, C, Wright, J., and Orkin, S.H.(1988) Induction of phagocyte cytochrome b heavy chain gene expression by interferon gamma. Proc. Natl. Acad. Sci. USA 85(14), 5215–5219.

    PubMed  CAS  Google Scholar 

  48. Ezekowitz, R.A., Dinauer, M.C., Jaffe, H.S., Orkin, S.H., and Newburger, P.E. (1988) Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. TV. Engl. J. Med. 319(3), 146–151.

    CAS  Google Scholar 

  49. Schiff, D.E., Rae, J., Martin, T.R., Davis, B.H., and Curnutte, J.T. (1997) Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood 90(8), 3187–3194.

    PubMed  CAS  Google Scholar 

  50. Aulitzky, W., Gastl, G., Aulitzky, W.E., Nachbaur, K., Lanske, B., Kemmler, G., et al. (1987) Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterinresponses. Immunobiology 176(1–2), 85–95.

    PubMed  CAS  Google Scholar 

  51. Ahlin, A., Elinder, G., and Palmblad, J. (1997) Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 89(9), 3396–3401.

    PubMed  CAS  Google Scholar 

  52. Jaffee, H.A., Buhl, R., Mastrangeli, A., Holroyd, K.J., Saltini, C, Czerski, D., et al. (1991) Organ specific cytokine therapy: local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon gamma to the human lung. J. Clin. Invest. 88, 297–302.

    Google Scholar 

  53. Kunzmann, V., Bauer, E., Feurle, J., Weissinger, F., Tony, H.P., and Wilhelm, M., (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2), 384–392.

    PubMed  CAS  Google Scholar 

  54. The International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324, 509–516.

    Google Scholar 

  55. Rex, J.H., Bennett, J.E., Gallin, J.I., Malech, H.L., DeCarlo, E.S., and Melnick, D.A. (1991) In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J. Infect. Dis. 163(4), 849–852.

    PubMed  CAS  Google Scholar 

  56. Bemiller, L.S., Roberts, D.H., Starko, K.M., Curnutte, J.T. (1995) Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol. Dis. 21, 239–247.

    PubMed  CAS  Google Scholar 

  57. Gallin, J.L, Farber, J.M., Holland, S.M., and Nutman, T.B. (1995) Interferon-gamma in the management of infectious diseases [clinical conference] [see comments]. Ann. Intern. Med. 123, 216–224.

    PubMed  CAS  Google Scholar 

  58. Jackson, S.H., Miller, G.F., Segal, B.H., Mardiney, M., III., Domachowske, J.B., Gallin, J.L, et al (2001) IFN-gamma is effective in reducing infections in the mouse model of chronic granulomatous disease (CGD). J. Interferon Cytokine Res. 21, 567–573.

    PubMed  CAS  Google Scholar 

  59. Key, L.L., Jr., Ries, W.L., Rodriguiz, R.M., and Hatcher, H.C., (1991) Recombinant human interferon gamma therapy for osteopetrosis. J. Pediatr. 121(1), 119–124.

    Google Scholar 

  60. Key, L.L, Jr., Rodriguiz, R.M., Willi, S.M., Wright, N.M., Hatcher, H.C., Eyre. D.R., et al. (1995) Long-term treatment of osteopetrosis with recombinant human interferon gamma. N. Engl. J. Med. 332(24), 1594–1599.

    PubMed  Google Scholar 

  61. Madyastha, P.R., Yang, S., Ries, W.L., and Key, L.L., Jr. (2000) IFN-gamma enhances osteoclast generation in cultures of peripheral blood from osteopetrotic patients and normalizes superoxide production. J. Interferon Cytokine Res. 20(7), 645–652.

    PubMed  CAS  Google Scholar 

  62. Hershman, M.J., Appel, S.H., Wellhausen, S.R., Sonnenfeld, G., and Polk, H.C., Jr. (1989) Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin. Exp. Immunol. 77(1), 67–70.

    PubMed  CAS  Google Scholar 

  63. Polk, H.C., Jr., Cheadle, W.G., Livingston, D.H., Rodriguez, J.L., Starko, K.M., Izu, A.E., et al. (1992) A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am. J. Surg. 163(2), 191–196.

    PubMed  Google Scholar 

  64. Dries, D.J., Jurkovich, G.J., Maier, R.V., Clemmer, T.P., Struve, S.N., Weigelt, J.A., et al. (1994) Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch. Surg. 129, 1031–1041.

    PubMed  CAS  Google Scholar 

  65. Kox, W.J., Bone, R.C., Krausch, D., Docke, W.D., Kox S.N., Wauer, H., et al. (1997) Interferon gamma-lb in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch. Intern. Med. 157(4), 389–393.

    PubMed  CAS  Google Scholar 

  66. Wasserman, D., Ioannovich, J.D., Hinzmann, R.D., Deichsel, G., and Steinmann, G.G. (1998) Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit. Care Med. 26(3), 434–439.

    PubMed  CAS  Google Scholar 

  67. Carvalho, E.M., Badaro, R., Reed, S.G., Jones, T.C., and Johnson, W.D., Jr. (1985) Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76(6), 2066–2069.

    PubMed  CAS  Google Scholar 

  68. Murray, H.W., Berman, J.D., and Wright, S.D. (1988) Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J. Infect. Dis. 157(5), 973–978.

    PubMed  CAS  Google Scholar 

  69. Badaro, R., Falcoff, E., Badaro, F.S., Carvalho, E.M., Pedral-Sampaio, D., Barral, A., et al. (1990) Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med. 322(1), 16–21.

    PubMed  CAS  Google Scholar 

  70. Badaro, R. and Johnson, W.D., Jr. (1993) The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J. Infect. Dis. 167(Suppl 1), S13-S17.

    PubMed  Google Scholar 

  71. Sundar, S., Rosenkaimer, F., and Murray, H.W. (1994) Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J. Infect. Dis. 170(3), 659–662.

    PubMed  CAS  Google Scholar 

  72. Sundar, S., Rosenkaimer, F., Lesser, M.L., and Murray, H.W. (1995) Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J. Infect. Dis. 171(4), 992–996.

    PubMed  CAS  Google Scholar 

  73. Sundar, S. and Murray, H.W. (1995) Effect of treatment with interferon-gamma alone in visceral leishmaniasis. J. Infect. Dis. 172(6), 1627–1629.

    PubMed  CAS  Google Scholar 

  74. Sundar, S., Singh, V.P., Sharma, S., Makharia, M.K., and Murray, H.W. (1997) Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 176(4), 1117–1119.

    PubMed  CAS  Google Scholar 

  75. Appelberg, R. and Orme, I.M. (1993) Effector mechanisms involved in cytokine-mediated bacteriostasis of Mycobacterium avium infections in murine macrophages. Immunology 80, 352–359

    PubMed  CAS  Google Scholar 

  76. Flesch, I.E. and Kaufmann, S.H. (1998) Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect. Immun. 56, 1464–1469.

    Google Scholar 

  77. Doherty, T.M. and Sher, A. (1997) Defects in cell-mediated immunity affect chronic, but not innate, resistance of mice to Mycobacterium avium infection. J. Immunol. 158, 4822–4831.

    PubMed  CAS  Google Scholar 

  78. Adams, L.B., Dinauer, M.C., Morgenstern, D.E., and Krahenbuhl, J.L. (1997) Comparison of the roles of reactive oxygen and nitrogen intermediates in the host response to Mycobacterium tuberculosis using transgenic mice. Tuberc. Lung Dis. 78, 237–246.

    CAS  Google Scholar 

  79. Cooper, A.M., Segal, B.H., Frank, A.A., Holland, S.M., and Orme, I.M. (2000) Transient loss of resistance to pulmonary tuberculosis in p47(phox-/-) mice. Infect. Immun. 68, 1231–1234.

    PubMed  CAS  Google Scholar 

  80. Bermudez, L.E. and Young, L.S. (1989) Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex. Microb. Pathol. 7, 289–298.

    CAS  Google Scholar 

  81. Denis, M., Gregg, E.O., and Ghandirian, E. (1990) Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages. Int. J. Immunopharmacol. 12, 721–727

    PubMed  CAS  Google Scholar 

  82. Douvas, G.S., Looker, D.L., Vatter, A.E., and Crowle, A.J. (1985) Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infect. Immun. 50, 1–8.

    PubMed  CAS  Google Scholar 

  83. Flynn, J.L., Chan, J., Triebold, K.J., Dalton, D.K., Stewart, T.A., and Bloom, B.R. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249–2254.

    PubMed  CAS  Google Scholar 

  84. Cooper, A.M., Dalton, D.K., Stewart, T.A., Griffin, J.P., Russell, D.G., and Orme, I.M. (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178, 2243–2247.

    PubMed  CAS  Google Scholar 

  85. Kamijo, R., Le, J., Shapiro, D., Havell, E.A., Huang, S., Aguet, M., et al. (1993) Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J. Exp. Med. 178, 1435–1440.

    PubMed  CAS  Google Scholar 

  86. Kamijo, R., Harada, H., Matsuyama, T., Bosland, M., Gerecitano, J., Shapiro, D., et al. (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263, 1612–1615.

    PubMed  CAS  Google Scholar 

  87. Edwards, C.K., III., Hedegaard, H.B., Zlotnik, A., Gangadharam, P.R., Johnston, R.B., Jr., and Pabst, M.J. (1986) Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J. Immunol. 136, 1820–1827.

    PubMed  CAS  Google Scholar 

  88. Hussain, S., Zwilling, B.S., and Lafuse, W.P. (1999) Mycobacterium avium infection of mouse macrophages inhibits IFN-gamma Janus kinase-STAT signaling and gene induction by down-regulation of the IFN-gamma receptor. J. Immunol. 163(4), 2041–2048.

    PubMed  CAS  Google Scholar 

  89. Ting, L.M., Kim, A.C., Cattamanchi, A., and Ernst, J.D. (1999) Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STATU. Immunol. 163(7), 3898–3906.

    CAS  Google Scholar 

  90. Nathan, C.F., Kaplan, G., Levis, W.R., Nusrat, A., Witmer, M.D., Sherwin, S.A., et al. (1986) Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N. Engl. J. Med. 315,6–15.

    PubMed  CAS  Google Scholar 

  91. Sampaio, E.P., Moreira, A.L., Sarno, E.N., Malta, A.M., and Kaplan, G. (1992) Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J. Exp. Med. 175, 1729–1737.

    PubMed  CAS  Google Scholar 

  92. Sampaio, E.P., Kaplan, G., Miranda, A., Nery, J. A., Miguel, C.P., Viana, S.M., et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168, 408–414.

    Google Scholar 

  93. Sampaio, E.P., Malta, A.M., Sarno, E.N., and Kaplan, G. (1996) Effect of rhuIFN-gamma treatment in multibacillary leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 64, 268–273.

    PubMed  CAS  Google Scholar 

  94. Haslett, P.A., Klausner, J.D., Makonkawkeyoon, S., Moriera, A., Metatratip, P., Boyle, B., et al. (1999) Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res. Hum. Retroviruses 15, 1169–1179.

    PubMed  CAS  Google Scholar 

  95. Bekker, L.G., Haslett, P., Maartens, G., Steyn, L., and Kaplan, G. (2000) Thalidominde-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J. Infect. Dis. 181, 954–965.

    PubMed  CAS  Google Scholar 

  96. Bermudez, L.E., Inderlied, C, and Young, L.S. (1991) Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob. Agents Chemother. 35, 2625–2629.

    PubMed  CAS  Google Scholar 

  97. Squires, K.E., Murphy, W.F., Madoff, L.C., and Murray, H.W. (1989) Interferon-gamma and Mycobacterium avium-intracellulare infection. J. Infect. Dis. 159, 599–600.

    PubMed  CAS  Google Scholar 

  98. Squires, K.E., Brown, S.T., Armstrong, D., Murphy, W.F., and Murray, H.W.(1992) Interferon-gamma treatment for Mycobacterium avium-intracellular complex bacillemia in patients with AIDS [letter]. J. Infect. Dis. 166, 686–687.

    PubMed  CAS  Google Scholar 

  99. Holland, S.M., Eisenstein, E.M., Kuhns, D.B., Turner, M.L., Fleisher, T.A., Strober, W., et al. (1994) Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N. Engl. J. Med. 330, 1348–1355.

    PubMed  CAS  Google Scholar 

  100. Levin, M., Newport, M.J., D’Souza, S., Kalabalikis, P., Brown, I.N., Lenicker, H.M., et al. (1995) Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? [see comments]. Lancet 345, 79–83.

    PubMed  CAS  Google Scholar 

  101. Vesterhus, P., Holland, S.M., Abrahamsen, T.G., and Bjerknes, R. (1998) Familial disseminated infection due to atypical mycobacteria with childhood onset. Clin. Infect. Dis. 27, 822–825.

    PubMed  CAS  Google Scholar 

  102. Jouanguy, E., Lamhamedi-Cherradi, S., Lammas, D., Dorman, S.E., Fondaneche, M.C., Dupuis, S., et al. (1999) A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection; [see comments]. Nat. Genet. 21, 370–378.

    PubMed  CAS  Google Scholar 

  103. Altare, F., Lammas, D., Revy, P., Jouanguy, E., Doffinger, R., Lamhamedi, S., et al. (1998) Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J. Clin. Invest. 102,2035–2040.

    PubMed  CAS  Google Scholar 

  104. Altare, F., Durandy, A., Lammas, D., Emile, J.F., Lamhamedi, S., Le Deist, F., et al. (1998) Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280, 1432–1435.

    PubMed  CAS  Google Scholar 

  105. de Jong, R., Altare, F., Haagen, I.A., Elferink, D.G., Boer, T., van Breda Vriesman, P.J., et al. (1988) Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280, 1435–1438.

    Google Scholar 

  106. Holland, S.M. (2000) Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect. 13, 1579–1590.

    Google Scholar 

  107. Chatte, G., Panteix, G., Perrin-Fayolle, M., and Pacheco, Y. (1995) Aerosolized interferon gamma for Mycobacterium aviwm-complex lung disease. Am. J. Respir. Crit. Care Med. 152, 1094–1096.

    PubMed  CAS  Google Scholar 

  108. Raad, I., Hachem, R., Leeds, N., Sawaya, R., Salem, Z., and Atweh, S. (1996) Use of adjunctive treatment with interferon-gamma in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain. Clin. Infect. Dis. 22, 572–574

    PubMed  CAS  Google Scholar 

  109. Condos, R., Rom, W.N., and Schluger, N.W. (1997) Treatment of multidrug-resistant pulmonary tuberculosis with interferon- gamma via aerosol, [see comments]. Lancet 349, 1513–1515.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Steven M. Holland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John I. Gallin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Surgery and Molecular Sciences, VA Medical Center, University of Tennessee, Memphis, TN, USA

    Malak Kotb PhD

  2. Division of Infectious Diseases, Department of Internal Medicine, Centre Hospital Universitaire Vaudois, Lausanne, Switzerland

    Thierry Calandra MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Holland, S.M., Gallin, J.I. (2003). Interferon-γ in the Treatment of Infectious Diseases. In: Kotb, M., Calandra, T. (eds) Cytokines and Chemokines in Infectious Diseases Handbook. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-309-5_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-309-5_23

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-247-6

  • Online ISBN: 978-1-59259-309-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation